Mainstream Capital Management LLC Takes Position in iShares Biotechnology ETF (NASDAQ:IBB)

Mainstream Capital Management LLC purchased a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,132 shares of the financial services provider’s stock, valued at approximately $150,000.

Other institutional investors have also recently made changes to their positions in the company. Huntington National Bank lifted its holdings in iShares Biotechnology ETF by 17.9% during the 3rd quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock worth $153,000 after purchasing an additional 160 shares in the last quarter. National Bank of Canada FI lifted its holdings in iShares Biotechnology ETF by 5.9% during the 3rd quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock worth $600,000 after purchasing an additional 229 shares in the last quarter. IFP Advisors Inc lifted its holdings in iShares Biotechnology ETF by 237.1% during the 4th quarter. IFP Advisors Inc now owns 16,018 shares of the financial services provider’s stock worth $2,118,000 after purchasing an additional 11,266 shares in the last quarter. Avior Wealth Management LLC raised its holdings in shares of iShares Biotechnology ETF by 438.2% in the 3rd quarter. Avior Wealth Management LLC now owns 3,229 shares of the financial services provider’s stock valued at $470,000 after acquiring an additional 2,629 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its holdings in shares of iShares Biotechnology ETF by 32.9% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock valued at $96,533,000 after acquiring an additional 164,000 shares in the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Down 2.0 %

NASDAQ:IBB opened at $134.24 on Tuesday. The business’s 50-day moving average price is $135.92 and its two-hundred day moving average price is $140.53. iShares Biotechnology ETF has a twelve month low of $123.60 and a twelve month high of $150.57. The stock has a market cap of $6.34 billion, a P/E ratio of 24.52 and a beta of 0.84.

iShares Biotechnology ETF Cuts Dividend

The firm also recently declared a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were issued a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.